Trypanosoma brucei is a digenetic protozoan parasite presenting a public health hazard in certain areas of Africa; it is transmitted between mammals (bloodstream form (BSF)) by tsetse flies (procyclic form (PCF)). We have an ongoing interest in small GTP proteins in T. brucei, and these are commonly isoprenylated. Many isoprenylated proteins belong to the rab family and include ras; the isoprene group, farnesyl (F) or geranylgeranyl (GG), is essential for function. The mevalonate pathway is conserved in all organisms studied, and provides F and GG, intermediates for sterol biosynthesis and dolichols and ubiquinone.
Protein isoprenylation has not before been demonstrated in T . brucei but was recently reported i n the protozoan Giardia lamblia [l] . Intermediates of the mevalonate pathway are present in T. brucei: interestingly, unusual short chain dolichols were found [2] . cDNAs encoding rabs are present in T. brucei [3, 4] and include the isoprenylation signal near the 3' end [4, HF and MCF unpublished] . The signal, a n amino acid motif known as the CAAX box, determines whether F or GG is added. Ras isoprenylation is a target for cancer therapy. We set out to characterise isoprenylation in T. brucei as a possible therapeutic target for this pathogen.
We have demonstrated protein isoprenylation in T. brucei similar to that in mammals. Compactin is a competitive inhibitor of the key homeostatically regulated enzyme of the mevalonate pathway, hydroxymethylglutaryl CoenzymeA reductase (HMG-R) and causes cytostasis in T. brucei as in animal cells. Proteins were metabolically labelled by [3H]-mevalonate added to compactin treated cells (Fig. 1) . Isoprene groups were isolated from [3H]-mevalonate labelled proteins (Fig. 2) and the F/GG ratio was similar in T. brucei and human cells.
The protein profile (Fig. 1) is largely similar to that of mammals and G. lamblia. However, in T. brucei some novel isoprenylated species are seen in the small GTPase region of the gel (bar). Interestingly, T. brucei 
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120 Tbnelhr BSF and PCF respond with different sensitivities to compactin: cytostatic concentrations are lOpM for BSF and 100pM for PCF (Fig. 3) compared to 30pM i n mammalian cells.
Compactin treated PCF and BSF show gross morphological changes. Ultrastructural studies show a primary lesion in compactin treated cells that differs to that of synvinolin, a second inhibitor of HMG-R [5] . Compactin treated cells develop an interconnected system of vacuoles in the area between the nucleus and flagellar pocket.
In summary, isoprenylation of proteins occurs in T. brucei by addition of F or GG groups to proteins from an intermediate generated from mevalonate, as in mammals. The differential sensitivity of BSF and PCF to compactin may reflect known differences i n steroid metabolism in the two life forms: PCF make the steroid ergosterol (61 and its HMG-R is 3-6 times more active than in BSF [71. BSF can use external cholesterol as a sterol source or synthesise cholesterol [2] . W e suggest that detailed study of this pathway may uncover novel targets for trypanocidal drug design.
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